Renaissance Pharma's daretabart receives FDA Fast Track designation for high-risk neuroblastoma

Renaissance Pharma Ltd announced receipt of US FDA Fast Track Designation for daretabart (hu1418K322A). The company's IND application for the drug in high-risk neuroblastoma was also cleared, enabling initiation of the SHINE Phase II/III trial in relapsed or refractory pediatric patients in the United States.

Daretabart is a humanised anti-GD2 monoclonal antibody licensed by Renaissance Pharma — a subsidiary of Essential Pharma — from St. Jude Children's Research Hospital. GD2 is a disialoganglioside expressed at high levels on the surface of neuroblastoma cells, and antibody-mediated targeting of this antigen has been clinically validated by dinutuximab, which is approved as part of standard consolidation therapy for newly diagnosed high-risk disease. Daretabart incorporates structural modifications intended to improve its tolerability profile relative to earlier anti-GD2 agents, though the clinical significance of those modifications will require prospective evaluation in the SHINE trial.

The program draws on Phase II data generated at St. Jude, published in the Journal of Clinical Oncology in 2021, which evaluated the antibody — referred to in that study as hu14.18K322A — as part of first-line chemoimmunotherapy and in the post-consolidation setting. That study reported a three-year event-free survival rate of 73.7% and an overall survival rate of 86.0% in newly diagnosed high-risk patients. Those results were generated in a non-randomized Phase II context and in a different patient population from the relapsed or refractory cohort that the SHINE trial will enrol, which limits direct extrapolation.

The US FDA's Fast Track Designation, granted concurrently with IND clearance, makes daretabart eligible for more frequent agency interactions during development and for rolling review of marketing application sections as they are completed. The designation does not itself alter the evidentiary standard required for approval. Renaissance Pharma also announced the manufacture of the first commercial-scale GMP batch of daretabart, which the company described as a supply readiness milestone ahead of trial initiation.

The competitive context for daretabart in high-risk neuroblastoma centres on the established role of anti-GD2 therapy in the disease. Dinutuximab (Unituxin, United Therapeutics) and dinutuximab beta (Qarziba, Apeiron Biologics/EUSA Pharma) are approved for use in high-risk neuroblastoma in the United States and Europe respectively, primarily in the post-consolidation maintenance setting for newly diagnosed patients. Naxitamab (Danyelza, Y-mAbs Therapeutics), another anti-GD2 antibody, received US FDA approval in 2020 for relapsed or refractory high-risk neuroblastoma in bone or bone marrow in patients who have demonstrated a partial response, minor response, or stable disease to prior therapy. The relapsed and refractory setting that SHINE targets therefore already has at least one approved anti-GD2 option in the United States, and daretabart's differentiation in that context will depend on the tolerability and efficacy data the trial generates.

Renaissance is a privately held subsidiary of Essential Pharma, a company whose portfolio spans rare disease and cardiorespiratory medicines across approximately 70 countries. Daretabart is described as the company's first development-stage asset. The scale of the organization relative to the established players in the neuroblastoma space means that manufacturing reliability and regulatory execution will be as consequential as clinical data in determining whether the program advances to a marketing application. The confirmed production of a commercial-scale GMP batch before trial initiation is consistent with that operational priority.

---

Spot something wrong? Report an issue with this article